Equities Analysts Issue Forecasts for MREO FY2025 Earnings

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) – Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research note issued to investors on Monday, November 24th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.06) per share for the year, up from their prior forecast of ($0.07). The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Other equities research analysts have also issued research reports about the stock. Zacks Research upgraded shares of Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. JPMorgan Chase & Co. raised their target price on Mereo BioPharma Group from $7.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Wall Street Zen upgraded Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mereo BioPharma Group in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Mereo BioPharma Group Stock Up 2.8%

MREO stock opened at $1.84 on Wednesday. The stock has a market cap of $292.80 million, a PE ratio of -30.67 and a beta of 0.41. The firm’s 50-day simple moving average is $1.91 and its 200 day simple moving average is $2.04. Mereo BioPharma Group has a fifty-two week low of $1.47 and a fifty-two week high of $3.94.

Mereo BioPharma Group (NASDAQ:MREO) last issued its earnings results on Monday, November 10th. The company reported ($0.01) earnings per share for the quarter.

Hedge Funds Weigh In On Mereo BioPharma Group

A number of hedge funds have recently modified their holdings of MREO. Monaco Asset Management SAM raised its position in shares of Mereo BioPharma Group by 9.2% during the first quarter. Monaco Asset Management SAM now owns 416,468 shares of the company’s stock worth $937,000 after purchasing an additional 35,000 shares during the period. BIT Capital GmbH acquired a new stake in Mereo BioPharma Group during the 1st quarter worth about $227,000. Aberdeen Group plc purchased a new stake in Mereo BioPharma Group during the first quarter valued at about $4,924,000. Tejara Capital Ltd boosted its holdings in shares of Mereo BioPharma Group by 8.8% in the first quarter. Tejara Capital Ltd now owns 2,521,324 shares of the company’s stock worth $5,673,000 after buying an additional 204,239 shares during the period. Finally, Forefront Analytics LLC increased its position in shares of Mereo BioPharma Group by 37.1% in the first quarter. Forefront Analytics LLC now owns 47,630 shares of the company’s stock worth $107,000 after acquiring an additional 12,877 shares in the last quarter. 62.83% of the stock is currently owned by institutional investors and hedge funds.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.